H

Hansoh Pharmaceutical Group Company Ltd
HKEX:3692

Watchlist Manager
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Watchlist
Price: 19.08 HKD 2.36% Market Closed
Market Cap: 113.2B HKD
Have any thoughts about
Hansoh Pharmaceutical Group Company Ltd?
Write Note

Hansoh Pharmaceutical Group Company Ltd
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Hansoh Pharmaceutical Group Company Ltd
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Total Liabilities & Equity
ÂĄ33B
CAGR 3-Years
17%
CAGR 5-Years
31%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Total Liabilities & Equity
ÂĄ17B
CAGR 3-Years
16%
CAGR 5-Years
17%
CAGR 10-Years
18%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Total Liabilities & Equity
ÂĄ48.2B
CAGR 3-Years
7%
CAGR 5-Years
13%
CAGR 10-Years
19%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Total Liabilities & Equity
ÂĄ54.4B
CAGR 3-Years
3%
CAGR 5-Years
3%
CAGR 10-Years
15%
C
CSPC Innovation Pharmaceutical Co Ltd
SZSE:300765
Total Liabilities & Equity
ÂĄ5.9B
CAGR 3-Years
23%
CAGR 5-Years
17%
CAGR 10-Years
N/A
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Total Liabilities & Equity
ÂĄ1.4B
CAGR 3-Years
11%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hansoh Pharmaceutical Group Company Ltd
Glance View

Market Cap
113.2B HKD
Industry
Pharmaceuticals

Hansoh Pharmaceutical Group Company Ltd., founded in 1995 and headquartered in Jiangsu, China, has rapidly evolved into one of the leading biopharmaceutical enterprises in the country. With a robust portfolio that spans biologics, small molecule drugs, and innovative therapies, Hansoh has carved a niche for itself by focusing on high-demand therapeutic areas such as oncology, central nervous system disorders, and autoimmune diseases. The company thrives on its commitment to research and development, partnering with academic institutions and international firms to drive innovation, which is pivotal in a competitive industry characterized by rapid technological advancements. Investors will find comfort in Hansoh's strong growth trajectory, marked by impressive revenue increases and a strategic intent to expand its footprint both domestically and globally. As the Chinese healthcare market continues to burgeon, driven by an aging population and evolving consumer demands, Hansoh Pharmaceutical is well-positioned to capitalize on these trends. Its recent listings on major global stock exchanges signal its ambition to attract international investors and strengthen its balance sheet for future endeavors. The company's strategic initiatives aim to diversify its product offerings and improve access to its innovative drugs, setting it apart from its competitors. With a management team that emphasizes prudent decision-making and value creation—echoing the principles of investment legends like Warren Buffett and Charlie Munger—Hansoh is not just a company; it is a growing story of success in the burgeoning pharmaceutical landscape that promises to deliver sustained value for its shareholders in the years to come.

Intrinsic Value
15.71 HKD
Overvaluation 18%
Intrinsic Value
Price
H

See Also

What is Hansoh Pharmaceutical Group Company Ltd's Total Liabilities & Equity?
Total Liabilities & Equity
33B CNY

Based on the financial report for Dec 31, 2023, Hansoh Pharmaceutical Group Company Ltd's Total Liabilities & Equity amounts to 33B CNY.

What is Hansoh Pharmaceutical Group Company Ltd's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
31%

Over the last year, the Total Liabilities & Equity growth was 10%. The average annual Total Liabilities & Equity growth rates for Hansoh Pharmaceutical Group Company Ltd have been 17% over the past three years , 31% over the past five years .

Back to Top